{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T23:53:02Z","timestamp":1777938782894,"version":"3.51.4"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T00:00:00Z","timestamp":1777680000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T00:00:00Z","timestamp":1777680000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Ophthalmol"],"DOI":"10.1007\/s10792-026-04092-w","type":"journal-article","created":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T04:51:13Z","timestamp":1777697473000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Switch to faricimab in various retinal diseases: real-world data"],"prefix":"10.1007","volume":"46","author":[{"given":"Eitan","family":"Kaplan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ori","family":"Segal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elad","family":"Moisseiev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-9755-182X","authenticated-orcid":false,"given":"GIlad","family":"Allon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,5,2]]},"reference":[{"issue":"1","key":"4092_CR1","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/s10792-025-03685-1","volume":"45","author":"WA Alsakran","year":"2025","unstructured":"Alsakran WA, Alsadoon AA, Alsayed B, Magliyah MS, Hb AL (2025) Clinical features and classification framework of polypoidal choroidal vasculopathy in Saudi populations. Int Ophthalmol 45(1):323. https:\/\/doi.org\/10.1007\/s10792-025-03685-1","journal-title":"Int Ophthalmol"},{"issue":"1","key":"4092_CR2","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.ophtha.2012.07.038","volume":"120","author":"JW Miller","year":"2013","unstructured":"Miller JW, Le Couter J, Strauss EC, Ferrara N (2013) Vascular endothelial growth factor a in intraocular vascular disease. Ophthalmology 120(1):106\u2013114. https:\/\/doi.org\/10.1016\/j.ophtha.2012.07.038","journal-title":"Ophthalmology"},{"key":"4092_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/cells10051049","author":"JO Wallsh","year":"2021","unstructured":"Wallsh JO, Gallemore RP (2021) Anti-VEGF-resistant retinal diseases: a review of the latest treatment options. Cells. https:\/\/doi.org\/10.3390\/cells10051049","journal-title":"Cells"},{"issue":"11","key":"4092_CR4","doi-asserted-by":"publisher","first-page":"2559","DOI":"10.1007\/s00417-019-04456-2","volume":"257","author":"C Hara","year":"2019","unstructured":"Hara C, Wakabayashi T, Fukushima Y, Sayanagi K, Kawasaki R, Sato S et al (2019) Tachyphylaxis during treatment of exudative age-related macular degeneration with aflibercept. Graefes Arch Clin Exp Ophthalmol 257(11):2559\u20132569. https:\/\/doi.org\/10.1007\/s00417-019-04456-2","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"10326","key":"4092_CR5","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/S0140-6736(22)00010-1","volume":"399","author":"JS Heier","year":"2022","unstructured":"Heier JS, Khanani AM, Quezada Ruiz C, Basu K, Ferrone PJ, Brittain C et al (2022) Efficacy, durability, and safety of intravitreal faricimab up to every 16\u00a0weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet 399(10326):729\u2013740. https:\/\/doi.org\/10.1016\/S0140-6736(22)00010-1","journal-title":"Lancet"},{"issue":"10326","key":"4092_CR6","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/S0140-6736(22)00018-6","volume":"399","author":"CC Wykoff","year":"2022","unstructured":"Wykoff CC, Abreu F, Adamis AP, Basu K, Eichenbaum DA, Haskova Z et al (2022) Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials. Lancet 399(10326):741\u2013755. https:\/\/doi.org\/10.1016\/S0140-6736(22)00018-6","journal-title":"Lancet"},{"key":"4092_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2025.03.005","author":"CJ Danzig","year":"2025","unstructured":"Danzig CJ, Dinah C, Ghanchi F, Hattenbach LO, Khanani AM, Lai TYY et al (2025) Faricimab treat-and-extend dosing for macular edema due to retinal vein occlusion: 72-week results from the BALATON and COMINO trials. Ophthalmol Retina. https:\/\/doi.org\/10.1016\/j.oret.2025.03.005","journal-title":"Ophthalmol Retina"},{"issue":"8","key":"4092_CR8","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/j.ophtha.2024.02.014","volume":"131","author":"AM Khanani","year":"2024","unstructured":"Khanani AM, Kotecha A, Chang A, Chen SJ, Chen Y, Guymer R et al (2024) TENAYA and LUCERNE: two-year results from the phase 3 neovascular age-related macular degeneration trials of faricimab with treat-and-extend dosing in year 2. Ophthalmology 131(8):914\u2013926. https:\/\/doi.org\/10.1016\/j.ophtha.2024.02.014","journal-title":"Ophthalmology"},{"issue":"1","key":"4092_CR9","doi-asserted-by":"publisher","first-page":"100111","DOI":"10.1016\/j.xops.2021.100111","volume":"2","author":"N Eter","year":"2022","unstructured":"Eter N, Singh RP, Abreu F, Asik K, Basu K, Baumal C et al (2022) YOSEMITE and RHINE: phase 3 randomized clinical trials of faricimab for diabetic macular edema: study design and rationale. Ophthalmol Sci 2(1):100111. https:\/\/doi.org\/10.1016\/j.xops.2021.100111","journal-title":"Ophthalmol Sci"},{"key":"4092_CR10","doi-asserted-by":"publisher","first-page":"3747","DOI":"10.2147\/OPTH.S231801","volume":"15","author":"AM Khanani","year":"2021","unstructured":"Khanani AM, Russell MW, Aziz AA, Danzig CJ, Weng CY, Eichenbaum DA et al (2021) Angiopoietins as potential targets in management of retinal disease. Clin Ophthalmol 15:3747\u20133755. https:\/\/doi.org\/10.2147\/OPTH.S231801","journal-title":"Clin Ophthalmol"},{"issue":"17","key":"4092_CR11","doi-asserted-by":"publisher","first-page":"3574","DOI":"10.1038\/s41433-023-02553-5","volume":"37","author":"AM Khanani","year":"2023","unstructured":"Khanani AM, Aziz AA, Khan H, Gupta A, Mojumder O, Saulebayeva A et al (2023) The real-world efficacy and safety of faricimab in neovascular age-related macular degeneration: the TRUCKEE study - 6 month results. Eye (Lond) 37(17):3574\u20133581. https:\/\/doi.org\/10.1038\/s41433-023-02553-5","journal-title":"Eye (Lond)"},{"issue":"18","key":"4092_CR12","doi-asserted-by":"publisher","first-page":"3569","DOI":"10.1038\/s41433-024-03364-y","volume":"38","author":"GA Borchert","year":"2024","unstructured":"Borchert GA, Kiire CA, Stone NM, Akil H, Gkika T, Fischer MD et al (2024) Real-world six-month outcomes in patients switched to faricimab following partial response to anti-VEGF therapy for neovascular age-related macular degeneration and diabetic macular oedema. Eye (Lond) 38(18):3569\u20133577. https:\/\/doi.org\/10.1038\/s41433-024-03364-y","journal-title":"Eye (Lond)"},{"issue":"3","key":"4092_CR13","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1111\/aos.16797","volume":"103","author":"A Arnold-Vangsted","year":"2025","unstructured":"Arnold-Vangsted A, Schou MG, Balaratnasingam C, Cehofski LJ, Chhablani J, van Dijk EHC et al (2025) Efficacy of intravitreal faricimab therapy for polypoidal choroidal vasculopathy: a systematic review and meta-analysis. Acta Ophthalmol 103(3):247\u2013256. https:\/\/doi.org\/10.1111\/aos.16797","journal-title":"Acta Ophthalmol"},{"key":"4092_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/life14040476","author":"A Machida","year":"2024","unstructured":"Machida A, Oishi A, Ikeda J, Kurihara J, Yoneda A, Tsuiki E et al (2024) Factors associated with success of switching to faricimab for neovascular age-related macular degeneration refractory to intravitreal aflibercept. Life (Basel). https:\/\/doi.org\/10.3390\/life14040476","journal-title":"Life (Basel)"},{"issue":"7","key":"4092_CR15","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1136\/bjophthalmol-2019-315746","volume":"105","author":"ZJ Chen","year":"2021","unstructured":"Chen ZJ, Ma L, Brelen ME, Chen H, Tsujikawa M, Lai TY et al (2021) Identification of TIE2 as a susceptibility gene for neovascular age-related macular degeneration and polypoidal choroidal vasculopathy. Br J Ophthalmol 105(7):1035\u20131040. https:\/\/doi.org\/10.1136\/bjophthalmol-2019-315746","journal-title":"Br J Ophthalmol"},{"issue":"2","key":"4092_CR16","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1167\/iovs.16-20575","volume":"58","author":"L Ma","year":"2017","unstructured":"Ma L, Brelen ME, Tsujikawa M, Chen H, Chu WK, Lai TY et al (2017) Identification of ANGPT2 as a new gene for neovascular age-related macular degeneration and polypoidal choroidal vasculopathy in the Chinese and Japanese populations. Invest Ophthalmol Vis Sci 58(2):1076\u20131083. https:\/\/doi.org\/10.1167\/iovs.16-20575","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"4092_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14072454","author":"M Hafner","year":"2025","unstructured":"Hafner M, Herold TR, Kufner A, Asani B, Anschutz A, Eckardt F et al (2025) Switching to faricimab in therapy-resistant macular edema due to retinal vein occlusion: initial real-world efficacy outcomes. J Clin Med. https:\/\/doi.org\/10.3390\/jcm14072454","journal-title":"J Clin Med"},{"issue":"3","key":"4092_CR18","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.ophtha.2020.08.006","volume":"128","author":"CMG Cheung","year":"2021","unstructured":"Cheung CMG, Lai TYY, Teo K, Ruamviboonsuk P, Chen SJ, Kim JE et al (2021) Polypoidal choroidal vasculopathy: consensus nomenclature and non-indocyanine green angiograph diagnostic criteria from the Asia-pacific ocular imaging society PCV workgroup. Ophthalmology 128(3):443\u2013452. https:\/\/doi.org\/10.1016\/j.ophtha.2020.08.006","journal-title":"Ophthalmology"},{"issue":"14","key":"4092_CR19","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1056\/NEJMoa054481","volume":"355","author":"PJ Rosenfeld","year":"2006","unstructured":"Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY et al (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355(14):1419\u20131431. https:\/\/doi.org\/10.1056\/NEJMoa054481","journal-title":"N Engl J Med"},{"key":"4092_CR20","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000004611","author":"TB Tew","year":"2025","unstructured":"Tew TB, Hsieh YT, Tsui MC, Hsia Y, Lee CY, Wang SW et al (2025) Comparison of characteristics and treatment outcomes of type 1 and type 2 myopic choroidal neovascularization after anti-vascular endothelial growth factor therapy. Retina. https:\/\/doi.org\/10.1097\/IAE.0000000000004611","journal-title":"Retina"},{"key":"4092_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-015-0025-z","volume":"15","author":"F Batioglu","year":"2015","unstructured":"Batioglu F, Demirel S, Ozmert E, Abdullayev A, Bilici S (2015) Short-term outcomes of switching anti-VEGF agents in eyes with treatment-resistant wet AMD. BMC Ophthalmol 15:40. https:\/\/doi.org\/10.1186\/s12886-015-0025-z","journal-title":"BMC Ophthalmol"}],"container-title":["International Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-026-04092-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10792-026-04092-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-026-04092-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T04:51:14Z","timestamp":1777697474000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10792-026-04092-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,2]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4092"],"URL":"https:\/\/doi.org\/10.1007\/s10792-026-04092-w","relation":{},"ISSN":["1573-2630"],"issn-type":[{"value":"1573-2630","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,2]]},"assertion":[{"value":"27 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and was approved by the Ethics Committee of Meir Medical Center (IRB Approval Number: MMC-0290-24) on December 15, 2024, with the need for written informed consent waived.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"The authors affirm that the human research participant provided informed consent for publication of the images in Fig.\u00a0\n                      \n                      .","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"220"}}